|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01779 LONGBIO-B
Nominal 
() | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | |
| Turnover | 0 | -- | 0 |
| Cost of Sales | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | |
| Profit / (Loss) before Taxation | (175,583) | 27.863% | (137,321) | |
| Taxation | 0 | -- | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | |
| Others | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (175,583) | 27.863% | (137,321) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 15,511 | -47.708% | 29,662 |
| Depreciation & Amortisation | 7,602 | 4.855% | 7,250 |
| Directors' Emoluments | 2,398 | 340.000% | 545 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | |
| EPS (cts) | -- | -- | -- |
| DPS (cts) | -- | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- |
| NBV per share ($) | -- | -- | -- |
| Remarks: | Real time quote last updated: 29/05/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -175,583 |
| %Change | 27.863% |
| EPS / (LPS) | RMB -- |
| NBV Per Share (¥) | RMB -- |